Petaluma biotech company Oculus Innovative Sciences saw annual revenue climb nearly 31 percent last year, with sales of its infection-fighting solution growing in the United States, Mexico, Europe and Asia.

Oculus posted $12.7 million in sales for the year ended March 31, compared to $9.8 million for the prior year, the company said Thursday.

Oculus lost $7.3 million last year, down from $7.9 million for the prior year.

The Petaluma company makes a family of products based on Microcyn, a solution for dermatology, oral care, surgical, wound care, animal health care and other markets.

Oculus reported $3.4 million in revenue for the fourth quarter, compared to $2.7 million for the same period last year.

Sales are growing in the U.S. as Oculus and its partners release new products, company CEO Hoji Alimi said.

"We expect U.S. revenues to increase in fiscal 2013 as our partners in the acute care and dermatology markets have recently launched multiple new Microcyn-based products," he said.